By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power
Health

Outliyr’s Independent Spectrometer Tests Find Popular Red Light Therapy Devices Delivering From 67 Percent to Nearly Triple Their Advertised Power

GlobeNews Wire
Last updated: 09/07/2026 6:43 AM
GlobeNews Wire
Published: 09/07/2026
Share
SHARE

Outliyr’s free public database catalogs more than seventy red light therapy panels and other light therapy devices, and publishes its own spectrometer measurements next to manufacturer claims for the units it has tested hands-on, seven so far.

July 08, 2026 18:30 ET  | Source: Outliyr


Austin, TX, July 08, 2026 (GLOBE NEWSWIRE) — Two light therapy devices tested on a calibrated spectrometer at the same twelve-inch distance their manufacturers advertise returned numbers far from the spec sheet: a full-spectrum lamp measured nearly three times its published irradiance, while a red and near-infrared panel delivered as little as 67 percent of its advertised figure. The readings come from a new public testing database from Outliyr that places independent instrument measurements next to the marketing claims shoppers currently rely on.

Red light therapy panels under test at the Outliyr lab, where measured irradiance is checked against each maker’s advertised figure.

Red light therapy buyers spend anywhere from a few hundred to several thousand dollars largely on one number: irradiance, the measure of how much light a device delivers. Almost no brand publishes an independent measurement of it, and the first like-for-like comparisons suggest the advertised figures can miss in either direction, often falling short.

The database catalogs more than seventy light therapy devices, most of them red and near-infrared panels and wearables, and publishes Outliyr’s own spectrometer measurements for the units it has tested hands-on, seven so far, with more in testing. Each tested device lists measured irradiance at a standardized twelve-inch distance, peak wavelengths, electromagnetic field readings, flicker behavior, and price, so a shopper can compare on measured data instead of marketing copy.

“Brands compete on one number, and hardly any of them let you verify it,” said Nick Urban, founder of Outliyr, a CHEK Functional Health Coach and a School of Biohacking Instructor. “I bought a two-thousand-dollar spectrometer and started measuring panels myself. Some miss their numbers. Some beat them. Either way, the shopper deserves the measured figure before spending a thousand dollars on the advertised one.”

Testing follows a published protocol built on five instruments: a Hopoocolor OHSP350IR spectroradiometer for irradiance and full spectral output, a Hopoocolor HPCS330P flicker analyzer, a Cornet ED88T Plus EMF meter, a Satic Shield EMI meter that reads dirty electricity in Graham-Stetzer units, and a wall-power meter for electrical efficiency. All sit inside the Outliyr Testing Lab, a public registry of 20 calibrated instruments across 10 measurement domains, whose thermal-imaging camera and digital oscilloscope also measure each panel’s heat distribution and power-supply integrity. Each panel is measured at five points in a cross pattern (center, top, bottom, left, and right) after a fifteen-minute warmup in a blackout environment, and tested devices are re-measured on a six-to-twelve-month cadence.

The database is free to browse in the light therapy device comparison database, and the full testing methodology and equipment list is public. Red light devices that are tested hands-on can also earn an Outliyr Verified record, a public, code-verifiable ledger of the measured data. The complete dataset, with custom data slices and commentary for reporters, lives in Outliyr’s open data library, free to republish with attribution.

The Outliyr Testing Lab: 20 calibrated instruments across 10 measurement domains behind every tested device.

About Outliyr

Outliyr is a health optimization platform and research hub for high performers, biohackers, and longevity seekers. Founded by Nick Urban in Austin, Texas, Outliyr independently tests biohacking, longevity, and health technology on professional instruments and publishes the measured results, so readers can act on data instead of marketing claims. Alongside its testing lab and product databases, Outliyr produces the High Performance Longevity podcast, a newsletter, and self-experimentation tools used by readers in more than 150 countries. The throughline is simple: cut the hype, measure what works, and help people extend their prime.

Press Inquiries

Nick
media [at] outliyr.com
530-426-2319
https://outliyr.com

NovaBay Pharmaceuticals Issues a Reminder of Important Information Regarding the Pending Special Dividend and Upcoming 2025 Annual Meeting
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Cannabis: The Gateway to Tomatoes? New Survey Says Yes
MEDVi QUAD Claims Evaluated: Real Online Doctor-Approval ED Medication for Men’s Sexual Performance
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Artelo Biosciences Announces .0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Health

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNews Wire
GlobeNews Wire
27/03/2026
Bybit Becomes First Major Crypto Exchange to Integrate Western Union’s USDPT Stablecoin, Bridging Two Financial Worlds Through One Stablecoin
EnKash Unveils India’s First Unified Corporate Card Ecosystem for Businesses
Delta Clinics Reports Increase in Demand for Body Contouring Treatments
ECOVACS Launches DEEBOT N50 Pro All-In-One With 25,000 Pa Suction & 100% Edge Coverage At 64,999 — Engineered for Indian Homes
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?